BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1182@pharmaconomics
DTSTAMP:20260707T033905Z
DTSTART;VALUE=DATE:20260602
DTEND;VALUE=DATE:20260603
SUMMARY:AZN Phase 1 — camizestrant
DESCRIPTION:Phase 1 trial results for camizestrant in HR-positive\, HER2-negative advanced breast cancer are due Jun 2\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/901832/000165495426005381/a7798f.htm\n\nTrack it: https://pharmaconomics.com/e/1182
URL:https://pharmaconomics.com/e/1182
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:AZN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR